Metal Aryls
Sigma Aldrich 3'-Chloropropiophenone
MilliporeSigma Sigma Organics products encompass a wide range of quality reagents, solvents, catalysts, and building blocks for organic synthesis. From benchtop discovery to process development and scale-up, Sigma Organics solutions are built to meet the needs of synthetic chemists.
Sigma Aldrich 2-tert-Butylcyclohexanol, mixture of isomers
MilliporeSigma Sigma Organics products encompass a wide range of quality reagents, solvents, catalysts, and building blocks for organic synthesis. From benchtop discovery to process development and scale-up, Sigma Organics solutions are built to meet the needs of synthetic chemists.
Sigma Aldrich N,N-Dimethylthioformamide
MilliporeSigma Sigma Organics products encompass a wide range of quality reagents, solvents, catalysts, and building blocks for organic synthesis. From benchtop discovery to process development and scale-up, Sigma Organics solutions are built to meet the needs of synthetic chemists.
Sigma Aldrich Triphenylantimony(III)
MilliporeSigma Sigma Organics products encompass a wide range of quality reagents, solvents, catalysts, and building blocks for organic synthesis. From benchtop discovery to process development and scale-up, Sigma Organics solutions are built to meet the needs of synthetic chemists.
Medchemexpress LLC Triphenyltin chloride-d15 | 358731-94-9 | MFCD01861652 | 99.7% | 400.57 g/mol | C18D15ClSn | 5 MG
Triphenyltin chloride-d15 is the deuterium-labeled analogue of triphenyltin chloride used as a stable isotope reference standard and research reagent for analytical chemistry, mass spectrometry, and isotopic labeling studies. It is supplied as a powder and characterized by high isotopic enrichment and chemical purity.
- Deuterium-labeled standard for analytical and mass spectrometry applications.
- High chemical purity and isotopic enrichment for accurate quantitation.
- Supplied as a stable powder with defined storage conditions.
- Useful as an internal standard and reference material in method development.
- Characterized by molecular formula C18D15ClSn and molecular weight 400.57 g/mol.
Medchemexpress LLC ABT-639 | 1235560-28-7 | 99.3% | 455.91 | 100 MG
ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. It effectively blocks recombinant human T-type (Cav3.2) Ca2+ channels and attenuates low voltage-activated currents in rat DRG neurons. With high oral bioavailability and low brain:plasma ratio, it demonstrates dose-dependent antinociception in models of knee joint pain and increases tactile allodynia thresholds in neuropathic pain models.
- Selective T-type Ca2+ channel blocker
- High oral bioavailability
- Low protein binding
- Low brain:plasma ratio
- Produces antinociception in knee joint pain models
- Increases tactile allodynia thresholds in neuropathic pain models
- Does not significantly alter hemodynamic or psychomotor function at higher doses
Medchemexpress LLC ABT-639 | 1235560-28-7 | 99.3% | 455.91 | 50 MG
ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. It is used for research purposes only and not sold to patients. It effectively reduces nociceptive and neuropathic pain in rats.
- Blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion.
- Attenuates low voltage-activated (LVA) currents in rat DRG neurons.
- Significantly less active at other Ca2+ channels (e.g., Cav1.2 and Cav2.2).
- High oral bioavailability (%f=73) in rodents.
- Low protein binding (88.9%) in rodents.
- Low brain:plasma ratio (0.05:1) in rodents.
- Produces dose-dependent antinociception in a rat model of knee joint pain.
- Increases tactile allodynia thresholds in multiple models of neuropathic pain.
- Does not significantly alter hemodynamic or psychomotor function at higher doses.
Medchemexpress LLC ABT-639 | 1235560-28-7 | 99.3% | 455.91 | 5 MG
ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. It is for research use only and not sold to patients.
- Novel, peripherally acting, selective T-type Ca2+ channel blocker.
- Blocks recombinant human T-type (Cav3.2) Ca2+ channels (IC50=2 μM).
- Attenuates low voltage-activated (LVA) currents in rat DRG neurons (IC50=8 μM).
- Less active at other Ca2+ channels (e.g., Cav1.2, Cav2.2) (IC50>30 mM).
- High oral bioavailability (%F=73), low protein binding (88.9%), low brain:plasma ratio (0.05:1) in rodents.
- Produces dose-dependent antinociception in rat model of knee joint pain (ED50=2 mg/kg, p.o.).
- Increases tactile allodynia thresholds in multiple models of neuropathic pain (10-100 mg/kg, p.o.).
- Does not attenuate hyperalgesia in inflammatory pain models.
- Does not significantly alter hemodynamic or psychomotor function at higher doses (e.g., 100-300 mg/kg).